<!doctype html><html lang="zh-hans"><head><meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title>如何解决老化 How to Solve Aging</title><link rel="stylesheet" href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" integrity="sha384-ggOyR0iXCbMQv3Xipma34MD+dH/1fQ784/j6cY/iJTQUOhcWr7x9JvoRxT2MZw1T" crossorigin="anonymous"><link rel="stylesheet" href="/img/css.css?random="><link data-rh="true" rel="icon" href="/img/favicon.ico"/><script data-ad-client="ca-pub-6067137220025946" async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script><script type="text/javascript" src="https://platform-api.sharethis.com/js/sharethis.js#property=5effb96910009800120b8d4d&product=inline-share-buttons" async="async"></script>
<script>var _hmt = _hmt || [];(function() {var hm = document.createElement("script");hm.src = "https://hm.baidu.com/hm.js?03c1a0f31299b4a2fbb83c34d6beaac9";var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s);})();</script></head><body><div id="my_header"><div class="container"><nav class="navbar navbar-expand-lg"><a class="navbar-brand" href="/"><img alt="diglog" src="/img/logo.v1.gif" class="rounded-sm"></a><button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarNavAltMarkup" aria-controls="navbarNavAltMarkup" aria-expanded="false" aria-label="Toggle navigation"><span class="navbar-toggler-icon"></span></button><div class="collapse navbar-collapse" id="navbarNavAltMarkup"><div class="navbar-nav"></div></div></nav></div></div><div class="container"><div id="my_content"><h1 class="page_narrow">How to Solve Aging<br/>如何解决老化 </h1><div class="row"><div class="col-lg-12 col-12"><div class="my_story_list_item shadow p-3 mb-5 bg-white rounded"><div class="story_page_pub_time page_narrow">2021-05-12 09:42:41</div><div class="page_narrow text-break page_content"><p>Answers to this question can be found online in the forms of shorter and longer term roadmaps. One could infer an answer from  SENS or get a list of ideas from Celine Halioua&#39;s recent take on the matter (On what  the field needs rather than how to deal with the problem itself). This is just my view.</p><p>这个问题的答案可以以更短和长期路线图的形式在线找到。人们可以从Sens（Celine Halioua）从Celine Halioua获得答案列表，最近接受此事（关于现场需要的是如何处理问题本身）。这只是我的观点。</p><p> An important question for anyone wanting to answer &#34;How to solve aging&#34; is &#34;If aging is solved, have we then made a given individual, in normal conditions, immortal?&#34; Or &#34;Have we thus made it not immortal but negligibly senescent instead?&#34;. Or in other words, once aging is dealt with, how much work is left to do for medicine? Ultimately that&#39;s the goal, lest we want the aging field to end up like  nanotechnology, that once aspired to the great lofty goal of  atomically precise manufacturing but ended up small-minded due to PR concerns with the more visionary and ambitious goals of the early days.</p><p> 对于想要回答的人和＃34的任何人都有一个重要问题;如何解决老化＆＃34;是＆＃34;如果衰老得到解决，我们会在正常情况下制作给定的个人，不朽？＆＃34;或者＆＃34;我们这样做的不是不朽而是可忽略的衰老，而不是呢？＆＃34;或者换句话说，一旦衰老被处理，留下了多少工作的药物？最终，最终是我们希望老化领域最终像纳米技术一样最终，这是曾经渴望着原子上精确制造的巨大崇高目标，但由于PR与众多有远见和雄心勃勃的目标，最终令人难以置疑早期。</p><p> An additional point to have in mind when thinking about the question is the the geroscience hypothesis, this is the idea that a  small number of targets or pathways can have an impact on multiple diseases at once. This is not the claim that all disease can be treated in this way, just the more modest claim that instead of the usual Pharma approach of one disease : one target, we can find one target for multiple diseases.</p><p> 在思考问题的时候有一个额外的一点是Geroscience的假设，这是少数靶或途径可以一次对多种疾病产生影响的想法。这不是所有疾病都可以以这种方式对待的声明，这只是更适中的声明，而不是一种疾病的通常药物方法：一种靶，我们可以找到多种疾病的一个目标。</p><p> My  own answer to &#34;what is aging&#34;, and the  broader reading I&#39;ve done leads me to believe that under a plausible (but not the only possible) definition the answer is no, once aging (in a narrow sense!) is solved we have not achieved either immortality or negligible senescence.</p><p> 我自己的回答＆＃34;老化＆＃34;以及更广泛的阅读我所做的导致我相信，在一个合理的（但不是唯一可能的）的定义下，答案是答案，曾经是答案（在狭义！）已经解决，我们没有实现不朽的不朽或可忽略不计的衰老。</p><p> In one plausible definition of aging, and coherent with the geroscience hypothesis, once we identify those targets that can be hit to affect multiple diseases, and modulate them in the right way, then we have cured aging; we would have taken this highly connected set of processes that leads to multiple diseases and ameliorated them at once, lengthening lifespan and healthspan.</p><p> 在一个合理的衰老定义中，并与Geroscience假设相干，一旦我们识别可能被击中的目标，以影响多种疾病，并以正确的方式调制它们，那么我们已经治愈了老化;我们将采取这种高度连接的流程，导致多种疾病，并立即改进它们，延长寿命和卫生钢。</p><p> But we would be leaving out those nodes of the network that are not as tightly connected to the rest and thus require particular attention. My go-to example is the gradual narrowing and stiffening of the arteries leading to cardiovascular disease. This may have multiple causes (Calcification of the arteries, systemic or local senescence, inflammation, and just circulating LDL getting stuck in the arteries), but the phenomenon itself is not a consequence of some process deteriorating as we age; aging may accelerate it but does not cause it in the first place. Even if we get rid of inflammation and senescence, by the nature of what cholesterol is and how arteries work, it will get stuck in there and lead to problems (if  children lived forever, this process alone, holding everything else constant would lead to mortality). It is not a matter of increased LDL production or decreased uptake, although of course everything else will modulate this accumulation process. It could be that holding everything constant still leads to cardiovascular disease at age 200 rather than age 60; not saying here that there aren&#39;t huge gains to be exploited by targeting aging in the narrow sense.</p><p> 但我们将留出那些没有像剩下紧密连接的网络的节点，因此需要特别注意。我的进一步是导致心血管疾病的动脉逐渐缩小和加强。这可能具有多种原因（钙化动脉，全身或局部衰老，炎症，并且只是循环LDL被困在动脉中），但这种现象本身并不是我们年龄劣化的过程恶化的结果;老龄化可能会加速它，但在第一位置不会导致它。即使我们摆脱炎症和衰老，通过胆固醇的性质以及如何工作，它将被困在那里并导致问题（如果孩子们永远活着，那么这个过程就可以持有其他一切恒定会导致死亡率）。这不是增加LDL生产或减少的摄取问题，尽管当然还有其他一切都会调节这种积累过程。可能是持有的一切恒定仍然导致200岁的心血管疾病，而不是60岁;在这里不言而喻，在狭义中瞄准老龄化，且巨大的收益。</p><p> On another, broader, view of aging as damage accumulation, we wouldn&#39;t care that we need a myriad of specific interventions to complement the main geroscience path to health. If arteries get stiffer and LDL builds up, we could theoretically fix that directly. This is hard to do and historically Pharma has focused not on this (damage removal; here  cyclodextrins) but on slowing down the damage (with statins, or various forms of  PCSK9 inhibition). But it&#39;s a necessity if one wants to comprehensively reverse all functional decline, or so it seems to me.</p><p> 在另一个，更广泛的，老龄化视为伤害积累的看法，我们不会在乎我们需要一个特定的干预措施来补充健康的主要大学生道路。如果动脉变得更硬，LDL建立起来，我们可以直接修复。这很难做到，历史上Pharma没有重点关注这个（损伤去除;这里是环糊精），但在减缓损伤（用他汀类药物或各种形式的PCSK9抑制）。但它＆＃39;如果想要全面地逆转所有功能下降，左右，它在我看来也是必要的。 </p><p> Could it be that aging broadly (all damage) and aging in the narrow sense (the tightly connected core processes that degrade but not all) are the same? That if we fix the latter we get a fix for the former for free? My intuition is that no, that we would still need targeted interventions, but it would be great to be wrong! The argument for this is the existence of classes of molecules ( long lived proteins, but also oxidized cholesterol and others) that we may never have had the capacity to naturally remove (or what&#39;e the same, that we can&#39;t remove in a sufficient amount), if so no amount of up/downregulation of anything will fix that (In  one proposal to address this, we&#39;d need to replace entire tissues or organs).</p><p>它可以广泛（所有损坏）和老化在狭义（劣化但不是全部的核心过程）是相同的吗？如果我们修复后者，我们免费获得前者的修复？我的直觉是不，我们仍然需要有针对性的干预措施，但是错了是很好的！这的论据是存在分子类（长寿命蛋白质，也氧化胆固醇等），我们可能永远不会有自然去除的能力（或者我们可以＆＃39的＆＃39; T以足够的数量取消），如果是这样，任何任何数量的上涨/下调任何东西都不会解决（在一个提议中解决这个问题，我们＆＃39; D需要替换整个组织或器官）。</p><p> Then, if that process has some way to lead to mortality without a way to compensate for it, that alone will lead to mortality [what we ultimately want to push back against, along with functional decline in general]. This is not to say of course that treating aging in the narrow sense will do nothing: it can still push back many diseases at once, which is a huge win. But going beyond that will require a comprehensive approach that goes beyond this.</p><p> 然后，如果该过程有某种方式导致死亡率的情况下没有一种方式来弥补它，那么单独将导致死亡率[我们最终想要推回，以及一般功能下降]。这不是在狭隘的意义上治疗老龄化的课程都不会说：它仍然可以立即推回许多疾病，这是一个巨大的胜利。但超越这将需要一种超越这一点的全面方法。</p><p> That comprehensive approach will have treating aging at its core, as well as scoping out what is left to do. It will involve the regular Pharma approach of listing all diseases and looking at why they happen. The geroscience optic is key here, usually if you&#39;re working on pancreatic cancer you look at the pancreas, if you are working on fixing dementia you look at the brain. But it could be that treating Alzheimer&#39;s requires fixing the  immune system, rather than doing anything to the neurons. Importantly, and unlike most of regular drug development that targets a single disease cause, a  cure for a condition will very likely involve  combined interventions, especially interventions that do not slow down or speed up the rate of accumulation of some molecule; rather interventions that are directly removal or addition. For Alzheimer&#39;s we may want to target various amyloids to clear then, get the immune system back in shape, reduce the various sources of inflammation, and perhaps the  cribriform plate as well. This is rarely ever tried! Let me repeat that:  We do have on the table multiple ways to address a disease; we suspect or know that diseases are multi-factorial and yet we rarely test interventions together (except in oncology).</p><p> 全面的方法将在其核心处理老龄化，以及根据要做的事情。它将涉及列出所有疾病的常规药物方法，并在为什么发生的原因。 Geroscience Optic是关键在这里，通常是，如果你在胰腺癌上工作，你看看胰腺，如果你正在努力修复你看看大脑的痴呆症。但它可能是治疗阿尔茨海默氏症，而不是修复免疫系统，而不是对神经元做任何事情。重要的是，与靶向单一疾病原因的大多数常规药物发育不同，一种病症的治疗方法非常可能涉及组合干预措施，尤其是不会减缓或加速一些分子的积累速率的干预措施;相当干预直接去除或添加。对于阿尔茨海默猿＆＃39;我们可能想要靶向各种淀粉样蛋白清除，然后使免疫系统呈重形状，减少各种炎症的源，也许是CRIBRIFICLIFING板。这很少尝试！让我重复：我们确实有多种方法来解决疾病;我们怀疑或知道疾病是多因素，但我们很少将干预措施（肿瘤学除外）。</p><p> It is very plausible that if a combination cures a disease each part of the combination should ameliorate it by some amount. But if we never try the combinations we&#39;ll never know if the effects are synergistic. Four drugs to treat Alzheimer&#39;s may yield a boring 10% reduction in cognitive decline, but what if together they effectively stop or  reverse the disease. We don&#39;t know. And there&#39;s no good scientific argument for why this is doomed to fail. There are, to be sure, incentive-based arguments for why doesn&#39;t happen more often:</p><p> 如果组合治愈疾病，组合的每一部分应通过一定量改善它，这是非常合理的。但如果我们从未尝试组合我们＆＃39;如果效果也不知道，如果效果也是协同作用。治疗Alzheimer的四种药物＆＃39; s可能会产生无聊的认知下降减少10％，但如果它们在一起，他们会有效地停止或逆转疾病。我们不知道。和＃39;对于为什么注定要失败，没有良好的科学论点。有人肯定地，为什么＆＃39的激励的论点更经常发生：</p><p> Scientists want to  understand how a disease works. Poking the system times four makes it difficult to see exactly what is causing what</p><p> 科学家想了解疾病的作用。戳活系统时代，四次使得难以确切地看到导致的内容</p><p> Entrepreneurs are not regulatory masochists: You can help a lot of people  and make a pile of money by dealing with the low hanging fruit first. What would a Phase I or II trial look like if you have 4 therapies going on? How many combinations of dosage would you have to test? Not that this is impossible: we see this sort of setup in oncology, but it may be because it&#39;s a very visible life-threatening condition and even if the treatment harms the patient they were not going to live that long anyway so maybe the FDA is more chill with oncologists than with everyone else, who knows.</p><p> 企业家不是监管受虐狂：你可以帮助很多人，并首先处理低悬挂水果制作一堆钱。一阶段I或II试验看起来像4个疗法继续吗？您需要测试多少个剂量？不是那个是不可能的：我们在肿瘤学中看到了这种设置，但它可能是因为它＆＃39;即使治疗危害患者，也许也许FDA与肿瘤学家更加寒意，而不是与其他人一起认识。</p><p> Summing up, there are two things we should be doing more of to treat aging in the broad sense</p><p> 总结，我们应该在广泛的意义上做更多的事情来治疗老龄化 </p><p> 1 to N treatments (the geroscience approach) where one (1) drug can ameliorate multiple (N) diseases</p><p>1至N治疗（Geroscience方法）其中一种（1）药物可以改善多种（n）疾病</p><p> N to 1 treatments (the combinatorial approach) where a number of interventions (N) is concurrently tested to treat a single (1) condition</p><p> n至1个处理（组合方法），其中许多干预措施（n）被同时测试以治疗单个（1）条件</p><p>  Aging 1.0 is the classic geroscience (1toN) approach via a set of  usual suspects (mTOR, calorie restriction, IGF-1). This has been at the core of the field since its inception, they are the most robust interventions we know, and I have nothing against them, but it&#39;s important to note that there is geroscience beyond this. These will probably be the first interventions to hit the clinic in some form. (Off-label, some  already have)</p><p>  老化1.0是经典的Geroscience（1ton）方法，通过一组通常的嫌疑人（MTOR，卡路里限制，IGF-1）。自成立以来，这一直处于该领域的核心，它们是我们所知道的最强大的干预措施，而且我对他们没有任何反对，而是＆＃39;很重要的是，重要的是要注意这一点。这些可能是以某种形式击中诊所的第一个干预措施。 （偏出标签，有些已经有）</p><p> Aging 2.0 is a set of novel interventions that seem to have systemic effects but that are not that well characterized yet (As are reprogramming or the family of interventions adding/removing factors directly from blood). This is where we are now.</p><p> 老化2.0是一组似乎具有全身效应的新型干预措施，但这并不具备很好的表征（因为重新编程或者干预的家庭直接从血液中加入/去除因素）。这是我们现在的位置。</p><p> Aging 3.0 is the concurrent deployment of 1toN and Nto1 interventions together. This will benefit from a deep understanding of the individual interventions and diseases.</p><p> 老化3.0是联合顿顿和NTO1干预的同时部署。这将受益于对个体干预和疾病的深刻理解。</p><p> In practice what does the road to get there look like? My bias is in the science (You could make the FDA go away and be able to yolo trials through but that wouldn&#39;t solve the core of the problem). I believe with Celine that the first aging drug could be approved this decade. But what happens next? The science is just not there yet. Here are some things (not necessarily all the things!) that I think the field needs:</p><p> 在实践中，到达那里的道路是什么样的？我的偏见是科学（你可以让FDA消失，能够通过yolo试验，但是解决问题的核心）。我相信席琳，这十年可以批准第一台老化药物。但接下来会发生什么？科学只是不在那里。以下是一些事情（不一定是所有的事情！）我认为现场需求：</p><p> Funding for combined interventions. Take a single disease and roadmap an ideal way to target it in a combinatorial way. Multi-omic approaches may be helpful here to see exactly what one intervention does  or does not then use that to see what else it should be combined with.</p><p> 合并干预措施的资金。采取单一疾病和路线图，以组合方式瞄准它的理想方式。多OMIC方法可以帮助这里看到一个干预所做的任何干预或不使用它来看看它应该与之结合的内容。 </p><p> Aging biomarkers. To treat aging in the narrow sense we  could go to the FDA and say that drug D will decrease multimorbidity (a composite of various disease events). Great! But this trial will take a long time. Imagine having to wait 30 years to approve a statin. Instead, we need the LDL of aging, some biomarker that is related to multiple conditions that can be shown to causally influence them. Then, an intervention can use this as a surrogate endpoint and quickly validate the intervention.  Clocks may be used to this end if properly validated.</p><p>老化生物标志物。为了治疗狭窄的衰老，我们可以去FDA并说药物D会减少多重药（各种疾病事件的复合物）。伟大的！但这项试验需要很长时间。想象一下，必须等待30年才能批准他汀类药物。相反，我们需要衰老的LDL，一些与多种条件相关的生物标志物，可以显示出导致影响它们的多种条件。然后，干预可以将其用作代理端点，并快速验证干预。如果正确验证，时钟可能用于此目的。</p><p> Better animal models. From younger B6 mice to diverse, aged mice. These are more expensive so would require partnerships and investments in upstream suppliers (CROs like JAX or Charles Rivers)</p><p> 更好的动物模型。从年轻的B6小鼠到不同的老年老鼠。这些更昂贵，所以需要在上游供应商（像JAX或Charles Rivers这样的CROS）的伙伴关系和投资）</p><p> Moving past the hallmarks of aging to a quantitative, causal, understanding of the drivers of aging. To a first order approximation, everything is affecting everything else in nasty  loopy ways. But  how  much? We need to poke at the network of cause and effect that is aging to see how things are connected.</p><p> 将老化的标志转移到定量，因果，对老龄司机的理解。到一个阶级近似，一切都以令人讨厌的循环方式影响了其他所有内容。但是多少？我们需要在老化的原因和效果网络上戳，看看有关如何连接。</p><p> Information collection. The aging field is complex! Biology is complex! I wrote the  Longevity FAQ to give a primer to the field, but there are  many, many, many more things out there. We would benefit from more synthesis work done by interdisciplinary experts. Imagine having a resource such that if you read it you are confident you don&#39;t need go chase information anywhere else because what&#39;s relevant has been already added there (This of course would need constant updates and the ability to express dissenting views as well as being able to choose the level of depth you want to go down to). But solving this problem would help point researchers, entrepreneurs, and policymakers in better directions.</p><p> 信息收集。老化字段很复杂！生物学很复杂！我写了长寿常见问题解答给这个领域的底漆，但有很多，很多东西都在那里。我们将从跨学科专家完成的更多综合工作中受益。想象一下，如果你读它，那么如果你读到它，你就会有助于你不需要去追逐信息，因为它已经在那里添加了＆＃39;这当然需要不断更新和表达能力异议观点以及能够选择您想要缩短的景观）。但解决这个问题将有助于研究人员，企业家和政策制定者更好的方向。</p><p> More people! Especially more researchers. But also people playing various forms of coordination roles across labs.</p><p> 更多的人！特别是更多的研究人员。但人们还在实验室中发挥了各种形式的协调作用。</p><p> More human tests. We need the aging biomarkers for this for robustness, but ultimately we need to take these interventions to humans. This can be done academically especially if the interventions have already been FDA approved, as with the  Fahy work on thymic regeneration, the  AMBAR study for albumin replacement or  PEARL for rapamycin.</p><p> 更多人类测试。我们需要稳健的衰老生物标志物，但最终我们需要将这些干预措施带给人类。这可以特别是如果干预措施已经批准的干预措施，那么与FDA批准的干预措施，就像对胸科再生的那样，对雷帕霉素的白蛋白替代或珍珠的amar研究。</p><p> Tooling. This is not just for aging but in general the history of science is the history of the struggle against the lack of good quality data. In some areas (as in some branches of physics), principled thinking may yield insight without having to measure anything (We&#39;ve been confirming Einstein&#39;s hot takes since he proposed them, and he did not need fancy telescopes or Big Data to come up with General Relativity), but in biology it seems that the acquisition of better tools to perturb cells and organisms and measure their changes in detail is key. There is a  growing list of -seqs out there as are delivery mechanisms for novel therapeutical modalities. But... wouldn&#39;t it be nice to have more?</p><p> 工具。这不仅仅是为了老化，但在普遍上，科学史是争取缺乏优质数据的斗争。在某些地区（如物理分支机构），原则思维可能会产生洞察力，而无需衡量任何东西（我们＆＃39; ve一直在确认爱因斯坦＆＃39;自提议他们以来，他不需要花哨的望远镜或者大数据提出一般相对论），但在生物学中，似乎获取更好的工具给扰动细胞和生物并衡量它们的细节变化是关键。在那里有一个日益增长的-seqs列表，作为新的治疗方式的递送机制。但是......＆＃39;有更多的东西吗？ </p><p>   Ricón, José Luis, “How to solve aging”, Nintil (2021-05-08), available at https://nintil.com/how-to-solve-aging/.</p><p>ricón，joséluis，“如何解决老化”，第nintil（2021-05-08），在https://nintil.com/how-to-solve-plile/提供。 </p></div><div id="story_share_this"><div class="sharethis-inline-share-buttons"></div></div><div class="text-break sotry_link page_narrow"><a target="_blank" href="https://nintil.com/how-to-solve-aging">https://nintil.com/how-to-solve-aging</a></div><div class="story_tags page_narrow"><button type="button" class="btn btn-light my_tag"><a href="/tag/解决/">#解决</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/solve/">#solve</a></button><button type="button" class="btn btn-light my_tag"><a href="/tag/疾病/">#疾病</a></button></div></div><div class="my_movie_list_item shadow p-3 mb-5 bg-white rounded"><button type="button" class="btn btn-link my_tag"><a href="/tag/web2.0/">#web2.0</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/google/">#google</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/设计/">#设计</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/创意/">#创意</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/摄影/">#摄影</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/图片/">#图片</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/游戏/">#游戏</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/软件/">#软件</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/视频/">#视频</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/广告/">#广告</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/手机/">#手机</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/iphone/">#iphone</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/网站/">#网站</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/免费/">#免费</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/下载/">#下载</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/windows/">#windows</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/apple/">#apple</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/微软/">#微软</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/firefox/">#firefox</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/blog/">#blog</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/苹果/">#苹果</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/音乐/">#音乐</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/博客/">#博客</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/wordpress/">#wordpress</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/恶搞/">#恶搞</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/qq/">#qq</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/艺术/">#艺术</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/web/">#web</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/工具/">#工具</a></button><button type="button" class="btn btn-link my_tag"><a href="/tag/分享/">#分享</a></button></div></div></div><div id="my_footer"><div class=""><a href="/tags/">tags</a> <a href="/users/">users</a></div>&copy;2012-2021 diglog.com </div></div></body></html>